Core Insights - Kura Oncology is participating in a fireside chat hosted by Barclays, indicating engagement with investors and analysts in the biotech sector [1] Company Overview - Troy Wilson serves as the President and Chief Executive Officer of Kura Oncology, while Brian Powl holds the position of Chief Commercial Officer [1]

Kura Oncology FY Conference Summary Company Overview - Kura Oncology (NasdaqGS: KURA) is a commercial-stage biopharmaceutical company focused on developing targeted therapies for liquid and solid tumors [2][3] Key Priorities for 2026 - Drive the launch of KOMZIFTI to achieve majority market share - Execute an aggressive development plan for ziftomenib (KOMZIFTI) throughout the treatment continuum, especially in frontline settings [2] Product Launch and Market Feedback - KOMZIFTI was approved in November of the previous year and has had a successful launch - Key opinion leaders (KOLs) have provided positive feedback on four differentiating factors: 1. Strong efficacy in relapsed refractory NPM1 mutant space 2. Differentiated safety profile 3. Combinability with other medications 4. Simplicity of once-daily dosing [5][6] Market Adoption and Payer Response - Rapid uptake from payers, with over 80% of private payers including KOMZIFTI in their policies within the first 90 days, exceeding benchmarks [9] Clinical Development Plans - Plans to move KOMZIFTI into earlier line settings, particularly frontline AML - Focus on the properties of ziftomenib and execution of clinical trials, with a goal of enrolling 1,300 patients in phase one studies [11][13] MRD Negativity and Patient Outcomes - Emphasis on achieving minimal residual disease (MRD) negativity as a key endpoint, with a benchmark of 45% MRD negativity after two cycles of intensive chemotherapy for NPM1 patients [23][25] - The goal is to demonstrate a clinically meaningful MRD negativity rate above 10%-15% [25] Combination Therapies and Future Studies - Ongoing studies include combinations of ziftomenib with other therapies, such as Venetoclax and azacitidine, showing an overall response rate (ORR) of almost 80% in relapsed refractory NPM1 settings [35] - Upcoming data updates expected in 2026, including frontline updates and combination studies with gilteritinib [31][39] Tipifarnib Development - Kura is also developing Tipifarnib for KRAS G12C mutant solid tumors, focusing on overcoming resistance mechanisms [51][66] - The combination of Tipifarnib with other therapies is being evaluated, with a focus on safety and tolerability [75][81] Safety Profile - The safety profile of Tipifarnib is reported to be favorable, with manageable adverse events primarily related to myelosuppression [79][81] Conclusion - Kura Oncology is positioned for significant growth in 2026 with a strong focus on the launch of KOMZIFTI and ongoing clinical trials for ziftomenib and Tipifarnib, aiming to address unmet needs in oncology [3][84]

Kura Oncology Conference Call Summary Company Overview - Kura Oncology is a fully integrated commercial stage precision oncology company - The lead program is ziftomenib (commercial name KOMZIFTI), a menin inhibitor approved for relapsed refractory NPM1 mutant AML - Ambitious development plan to move ziftomenib throughout the continuum of care in various combinations, including frontline opportunities with KOMET-017 studies [5][6] Key Points on Ziftomenib (KOMZIFTI) - Launch Experience: - Approved in mid-November 2025, with rapid market entry within a week - Initial revenue of approximately $2.1 million in the first few weeks post-launch [7][8] - Strong physician feedback highlighting efficacy, safety, compatibility with other agents, and once-daily dosing [8] - Market Access: - Over 84% of plans have included KOMZIFTI in their policies within the first three months [9] - Step edits favoring KOMZIFTI over competitors have been observed, indicating strong market momentum [11] - Market Size: - Estimated total addressable market (TAM) for relapsed refractory NPM1 mutant space is approximately $350 million to $400 million annually, with about 6,000 patients per year [15] - Frontline market TAM is estimated to be 20 times larger than the relapsed refractory market, driven by a larger patient population and longer treatment duration [18] - Clinical Development: - Plans to generate multiple clinical data sets in 2026, including combination studies with various regimens [22][23] - Data expected from KOMET-007, Ven/Aza combination, and gilteritinib combination studies [22] Darlifarnib (Farnesyltransferase Inhibitor) - Targeting resistance mechanisms common to multiple therapies, including tyrosine kinase inhibitors [40] - Ongoing studies in renal cell carcinoma and KRAS G12C mutated solid tumors, with updates expected in 2026 [42][44] - Potential to enhance the efficacy of existing therapies and address a large patient population [46] Partnerships and Financial Position - Global partnership with Kyowa Kirin for ziftomenib development and commercialization, with $180 million in additional milestones anticipated [28][31] - Strong cash position of approximately $667 million, allowing for continued development and commercial plans [60] Upcoming Milestones - Expected publications and data releases throughout 2026, including: - Ziftomenib plus Ven/Aza in relapsed refractory setting - Combination of ziftomenib plus 7 + 3 - Darlifarnib data in renal cell carcinoma and KRAS G12C settings [61][62] Competitive Landscape - Acknowledgment of emerging competition in the farnesyltransferase inhibitor space, with a focus on enhancing patient outcomes through combination therapies [48][49] Conclusion - Kura Oncology aims to establish leadership in the menin and farnesyltransferase inhibitor markets, with a strong focus on commercial execution and clinical development in 2026 [62]

Core Viewpoint - Kura Oncology, Inc. has granted inducement awards in the form of nonstatutory stock options to new employees as part of its 2023 Inducement Option Plan, aimed at enhancing employee retention and attracting talent [1][2]. Group 1: Inducement Awards - The Compensation Committee granted stock options to purchase 44,700 shares of common stock to four new employees [1]. - Each stock option has an exercise price of $8.68 per share, which is the closing price of the Company's common stock on March 2, 2026 [2]. - The stock options will vest over four years, with 25% vesting on the one-year anniversary and the remaining shares vesting monthly over the following 36 months [2]. Group 2: Compliance and Terms - The stock options are granted in accordance with Nasdaq Listing Rule 5635(c)(4) as an inducement material to the new employees' employment [1]. - The options are subject to the terms and conditions of the Company's 2023 Inducement Option Plan and an applicable stock option agreement [2].

Core Insights - Kura Oncology aims to differentiate its menin inhibitor, Komzifti, in the market, focusing on growth and achieving a leading share in relapsed/refractory NPM1-mutant AML [1][3] - The company reported $2.1 million in net product revenue for Komzifti in late 2025, with positive feedback from healthcare professionals regarding its efficacy and safety [2][6] - Kura's financial position remains strong with $667.2 million in cash at the end of 2025, despite a net loss of $81 million in Q4 [4][17] Commercial Strategy - Kura's near-term objectives include establishing Komzifti's market presence and expanding its use in frontline AML treatments [1][11] - The company has engaged payers covering approximately 90% of insured lives, achieving rapid market access with 84% of private payers establishing coverage within 90 days of approval [8][9] - Komzifti was quickly added to NCCN guidelines as a Category 2A recommendation, reflecting strong support from clinical leaders [7] Product Development - Kura is advancing the KOMET-017 program to move ziftomenib earlier in AML treatment, with recruitment ongoing at around 200 sites [5][12] - The company is exploring combinations of ziftomenib with other therapies, including venetoclax and FLT3 inhibitors, to enhance treatment efficacy [13][14] - Data updates from ongoing trials are expected in 2026, which may support accelerated approval for ziftomenib in newly diagnosed AML [12] Financial Performance - Kura's Q4 2025 net product revenue was $2.1 million, marking a significant increase from the previous year [16] - The first commercial sale triggered a $135 million milestone payment, contributing to a strong cash position [4][17] - Collaboration revenue is projected to be between $45 million to $55 million in 2026, with expectations of continued funding for the ziftomenib program through 2028 [18] Future Outlook - Kura's 2026 priorities include accelerating Komzifti uptake, achieving quarter-over-quarter revenue growth, and executing its strategy to move ziftomenib to frontline treatment [19] - The company plans to publish combination data to guide treatment decisions and provide updates on its FTI platform [19]

Financial Data and Key Metrics Changes - Kura Oncology reported net product revenue of $2.1 million from Komzifti sales in Q4 2025, compared to none in Q4 2024 [16] - Collaboration revenue from the partnership with Kyowa Kirin was $15.2 million, down from $53.9 million in the same period in 2024 [16] - Research and development expenses increased to $64.4 million from $52.3 million in Q4 2024, driven by ziftomenib combination trials [16] - Sales, general, and administrative expenses rose to $39.1 million from $24.1 million in Q4 2024, attributed to the commercial launch of Komzifti [17] - The net loss for Q4 2025 was $81 million, compared to a net loss of $19.2 million in Q4 2024 [17] - Cash equivalents and short-term investments as of December 31, 2025, were $667.2 million, down from $727.4 million at the end of 2024 [17] Business Line Data and Key Metrics Changes - Komzifti generated $2.1 million in net product revenue shortly after its launch, indicating a strong start [3] - The initial U.S. market for NPM1-mutated relapse refractory AML is estimated at approximately $350 million to $400 million annually [10] - Kura anticipates a total U.S. opportunity across relapsed refractory and frontline AML of approximately $7 billion [4] Market Data and Key Metrics Changes - Prescription trends for Komzifti are strong, with positive feedback from physicians and pharmacists regarding its clinical activity and ease of use [7] - Approximately 84% of private payers established coverage for Komzifti within 90 days of approval, surpassing industry benchmarks [9] - Certain blue plans are requiring patients to use Komzifti before allowing coverage for other approved menin inhibitors, indicating a competitive advantage [9] Company Strategy and Development Direction - Kura's strategy focuses on executing commercially, expanding development of ziftomenib across the AML treatment continuum, and advancing a pipeline with meaningful catalysts in 2026 [5] - The company aims to position ziftomenib as a foundational combination partner in AML, including with FLT3 inhibitors and standard backbone regimens [4] - Kura is advancing a focused solid tumor strategy alongside its AML initiatives [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong early launch of Komzifti and its potential to establish leadership in the menin inhibitor class [6] - The company is focused on quarter-over-quarter growth, net revenue, and new patient starts, with plans to provide additional metrics to track progress [10] - Management highlighted the importance of combination therapies in driving better outcomes for patients and gaining market share [42] Other Important Information - Komzifti is now listed in the FDA's Orange Book with patent protection through July 2044, enhancing the long-term value of the franchise [4] - Kura expects to provide guidance for collaboration revenue of $45 million to $55 million in 2026, with anticipated milestones of $180 million under the collaboration agreement with Kyowa Kirin [18] Q&A Session Summary Question: Can you provide more information about the step editing policy from payers? - Management noted that some payers are recommending Komzifti before other menin inhibitors based on its differentiated profile, particularly its cost predictability and safety [25][26] Question: Can you comment on patient demand versus revenue generation? - Management indicated that the launch has been strong, with positive feedback from physicians and expectations for increased patient demand as more data becomes available [33] Question: What do you see as the biggest hurdle for Komzifti to gain market share in 2026? - Management identified the need to get incident patients onto therapy as a key challenge, with no significant payer hurdles reported [40] Question: How do you plan to maximize the FLT3 opportunity? - Management emphasized the importance of combining ziftomenib with FLT3 inhibitors to capture a significant portion of the AML market, as FLT3 mutations represent a large patient population [64] Question: What are the expectations for duration of therapy with Komzifti? - Management stated that while it is early to provide specific data, they expect patients to be treated for up to six months, with ongoing assessments of treatment duration as more data becomes available [87]

分组1 - Kura Oncology reported a quarterly loss of $0.92 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.72, and a significant increase from a loss of $0.22 per share a year ago, resulting in an earnings surprise of -28.67% [1] - The company posted revenues of $17.34 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 41.85%, and a decline from year-ago revenues of $53.88 million [2] - Kura Oncology shares have decreased by approximately 17.7% since the beginning of the year, contrasting with the S&P 500's gain of 0.4% [3] 分组2 - The earnings outlook for Kura Oncology is uncertain, with current consensus EPS estimates at -$0.95 on $18.37 million in revenues for the coming quarter and -$3.08 on $175.32 million in revenues for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 46% of over 250 Zacks industries, indicating that the industry outlook may negatively impact stock performance [8] - The estimate revisions trend for Kura Oncology was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

FDA Approval and Market Opportunity - The FDA approved KOMZIFTI (ziftomenib) on November 13, 2025, for treating adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation[22]. - The initial U.S. market opportunity for relapsed or refractory NPM1-mutated AML treatment is estimated at approximately $350.0 to $400.0 million annually, with a total annual market opportunity across relapsed or refractory and frontline AML estimated at approximately $7.0 billion[50]. - KOMZIFTI is the first and only menin inhibitor approved by the FDA for once-daily oral administration, enhancing patient compliance[45]. Clinical Trial Results - The complete remission (CR) rate plus CR with partial hematologic recovery (CRh) in the KOMET-001 trial was 21.4%, with a median duration of CR+CRh of five months[41]. - 88% of patients who achieved CR or CRh did so within six months of initiating KOMZIFTI[41]. - Among 51 patients with relapsed or refractory NPM1-mutated AML, the objective response rate was 65%, with a median overall survival of 54.9 weeks[71]. - The combination of ziftomenib with 7+3 chemotherapy demonstrated a 93% complete response rate in NPM1-mutated AML patients in the KOMET-007 trial[66]. - In the Phase 1 KOMET-007 trial, ziftomenib combined with venetoclax and azacitidine showed a 73% complete response rate in newly diagnosed NPM1-mutated AML patients[63]. Safety and Efficacy - The safety profile of KOMZIFTI was manageable, with most adverse events being Grade 1 or Grade 2, and no Grade 4 or Grade 5 QTc interval prolongation reported[42]. - Ziftomenib is expected to address up to 50% of AML cases, including those with NPM1 mutations and KMT2A rearrangements[58]. Development and Future Plans - The company plans to establish KOMZIFTI as the leading menin inhibitor in relapsed or refractory NPM1-mutated AML, aiming for majority class share[30]. - The clinical development program includes two registrational Phase 3 trials of ziftomenib in combination with chemotherapy for newly diagnosed AML[23]. - The company anticipates topline results from the MRD-negative complete response accelerated endpoint in the intensive chemotherapy setting by 2028[65]. - The company plans to advance its first next-generation menin inhibitor, KO-7246, into IND-enabling studies in diabetes and cardiometabolic diseases in 2026[92]. Competitive Landscape and Market Access - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may impact the development and commercialization of its products[122]. - At least 80% of private payors have established coverage policies for KOMZIFTI, with some requiring patients to use KOMZIFTI before other menin inhibitors[49]. - The market access team has engaged with 100% of targeted payor organizations responsible for coverage decisions affecting over 90% of insured lives prior to the launch of KOMZIFTI[131]. Regulatory and Compliance - The FDA approval process involves extensive regulation, including preclinical tests and clinical trials to establish safety and effectiveness[155]. - The FDA may require post-approval Phase 4 testing to confirm clinical benefits, with failure to conduct these trials potentially leading to market withdrawal[175]. - Compliance with various healthcare regulations is essential, as violations can lead to significant penalties and operational restrictions[206]. Financial and Corporate Structure - The company is eligible to receive up to $1.491 billion in total upfront and milestone payments under the Kyowa License Agreement, including $330 million for the expanded Field[118]. - As of December 31, 2025, the company has received or expects to receive a total of $592.6 million in upfront, milestone, and profit-sharing payments under the Kyowa License Agreement[118]. - The company has hired a field sales team with an average of over 20 years of industry experience to drive adoption of KOMZIFTI, targeting over 4,000 accounts[130]. Employee and Corporate Culture - As of December 31, 2025, the company employed 260 full-time employees, split evenly between research and development and administrative roles[216]. - The company invests in employee development through competitive compensation and wellness initiatives, overseen by senior management[217]. - The Code of Business Conduct and Ethics is implemented to ensure core values are upheld across operations, with annual training for all staff[218].

Core Insights - Kura Oncology's KOMZIFTI (ziftomenib) is generating early revenue momentum and has received positive feedback from the market, emphasizing its differentiated safety and convenience, which supports ongoing development plans targeting up to 50% of AML patients [1][2] Financial Performance - The company reported a net product revenue of $2.1 million in Q4 2025, based on approximately five weeks of commercial sales following the FDA approval on November 13 [5][13] - Collaboration revenue for Q4 2025 was $15.2 million, a decrease from $53.9 million in Q4 2024, reflecting non-cash revenue recognition under the collaboration agreement with Kyowa Kirin [13] - The net loss for Q4 2025 was $81.0 million, compared to $19.2 million for the same period in 2024 [13] Product Development and Pipeline - KOMZIFTI has been granted full FDA approval for adult patients with relapsed or refractory AML with a susceptible NPM1 mutation [5] - The company has initiated pivotal KOMET-017 Phase 3 frontline trials evaluating ziftomenib in combination with chemotherapy for patients with NPM1-m or KMT2A-rearranged AML [4] - Multiple clinical data milestones are expected in 2026 across AML and solid tumor programs, including ziftomenib's development in gastrointestinal tumors and darlifarnib in renal cell carcinoma [2][6] Market Position and Strategy - KOMZIFTI has been added to the NCCN Clinical Practice Guidelines as a Category 2A recommended treatment option for adults with R/R NPM1-m AML [5] - Approximately 80% of private payers established published coverage policies for KOMZIFTI within the first 90 days of its launch, all aligned with the label and without additional restrictions [5] - The company has a strong capital position with $667.2 million in cash and equivalents, expected to support the advancement of ziftomenib through to the topline results from the first pivotal Phase 3 trial anticipated in 2028 [8][9] Future Outlook - Kura expects 2026 to be a data-rich year with multiple potential value inflection points, including ongoing enrollment in pivotal trials and the advancement of next-generation therapies [6][9] - The company aims to establish clear differentiation in the menin inhibitor class and achieve leading class share in the R/R NPM1-m AML setting [7]

Kura Oncology Conference Call Summary Company Overview - Kura Oncology (NasdaqGS: KURA) is focused on developing therapies for cancer, particularly acute myeloid leukemia (AML) and solid tumors. [1] - The company is in a strong cash position, financed through top-line results in frontline AML. [4] Key Product: KOMZIFTI - KOMZIFTI is Kura's first commercial product, launched for NPM1-mutated AML, with a focus on establishing market leadership. [2] - The product has shown over 21% of patients achieving a Complete Response (CR) or CR with partial hematologic recovery, with a median duration of response of five months. [5][6] - Feedback from clinicians has been positive, highlighting efficacy, safety, and ease of use as differentiating factors. [9][10] Market Potential - The total addressable market (TAM) for relapsed refractory NPM1 mutant AML is estimated to be between $350 million and $400 million. [15] - Kura aims to capture a significant share of this market, with a consensus sales estimate of $48 million for KOMZIFTI in 2026. [12][13] Clinical Trials and Development - Kura is conducting two Phase 3 trials (KOMET-017) for KOMZIFTI, targeting both intensive and non-intensive chemotherapy options. [17][18] - The trial design allows for rapid site engagement and aims to cover a broad patient population. [18] - Kura is also exploring combinations with other agents, such as Quizartinib and Gilteritinib, to enhance treatment efficacy. [31][32] Competitive Landscape - Kura acknowledges competition from other companies developing menin inhibitors, such as Johnson & Johnson and Sumitomo, but believes it has a competitive edge due to its advanced development and market strategy. [36][37] Financial Position - Kura reported a cash balance of over $650 million, with additional milestones of $180 million tied to Phase 3 trials. [55] - The company is positioned to maintain operations through key value inflection points without immediate need for additional financing. [56] Future Outlook - Kura plans to release further clinical data in 2026, which is expected to validate its treatment mechanisms and support ongoing development efforts. [53] - The company is also pursuing regulatory approval in the EU for KOMZIFTI, aiming to enhance its market presence. [16] Additional Insights - Kura is exploring the use of menin inhibitors for diabetes and cardiometabolic diseases, indicating a potential expansion of its therapeutic focus. [4] - The company is committed to developing combination therapies in oncology, recognizing that AML is not typically treated with monotherapy. [33]